Belapectin, a galectin-3 inhibitor, for the treatment of NASH cirrhosis

December 2020, NASH summit

Pol F. Boudes, MD, Chief Medical Officer

NASDAQ: GALT

www.galectintherapeutics.com

2020 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Forward-looking statements

This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements.

These statements include those regarding potential therapeutic benefits of our drugs, expectations, plans and timelines related to our clinical trials, supporting activities, potential partnering opportunities and estimated spending for 2020 and beyond. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, our trials and supporting CMC information may be impacted by COVID-19.

We may experience delays in our trials, which could include enrollment delays. Future phases or future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Strategies and spending projections may change. We may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to complete our clinical trials or further develop and/or fund any future studies or trials.

To date, we have incurred operating losses since our inception, and our future success may be impacted by our

ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting

our business, see our Annual Report on Form 10-K for the year ended December 31, 2019, and our subsequent

filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent

2

events may cause our views to change, we disclaim any obligation to update forward-looking statements.

2020 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Belapectin targets and disrupts the function of galectin-3, which plays a major role in the progression of fibrotic diseases

Central role of Gal-3 in multiple pathological processes

Galectin-3 has the ability to link glycoproteins to form a lattice structure on the cellular surface and promote cell-cell and cell- matrix interactions

Galectin-3 expression is up-regulated in established human fibrotic liver disease, and disruption of Galectin-3 can markedly reduce liver fibrosis (*)

3

  • Henderson et al., PNAS, 2006.

2020 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

Schematic representation of Galectin-3: a carbohydrate recognition domain and a tail

4

2020 Galectin Therapeutics | NASDAQ: GALT

For more information, see galectintherapeutics.com

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Galectin Therapeutics Inc. published this content on 17 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 December 2020 17:42:04 UTC